查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589769

人工 T 细胞市场：按类型、应用和最终用户划分 - 全球预测 2025-2030

Engineered T Cells Market by Type (Chimeric Antigen Receptor, T Cell Receptor, Tumor-Infiltrating Lymphocytes), Application (Breast Cancer, Colorectal Cancer, Leukemia), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年人工T细胞市场价值为27.3亿美元，预计2024年将达到34.3亿美元，复合年增长率为25.72%，到2030年将达到135.6亿美元。

工程化 T 细胞主要用于免疫疗法，以修改患者的 T 细胞，以便更好地识别和攻击癌细胞。此系列包括嵌合体抗原受体 (CAR) T 细胞疗法和 T 细胞受体 (TCR) 疗法。对工程化 T 细胞的需求源于提供标靶癌症治疗的潜力，与传统治疗方法相比，副作用较少。它适用于各种血癌和一些固体癌。最终用途广泛，包括医院、研究机构和生技公司。基因编辑技术的进步、全球癌症发生率的增加以及私人和政府的大量投资推动了市场成长。主要商机在于开发现成的 T 细胞产品，以扩大在固体癌中的应用、改善安全性并提高可用性。然而，挑战包括高昂的处理成本、复杂的製造流程和监管障碍。市场限制，例如严重的副作用、復发的可能性以及对基因改造的伦理担忧也构成了障碍。用于精确基因编辑的 CRISPR-Cas9 创新、用于更好患者选择的新型生物标记物的开发以及自动化製造流程是应对这些挑战的关键。特别是，加深我们对肿瘤微环境的理解并解决癌细胞抗药性机制的研究是有前景的。与製药公司的合作、策略伙伴关係以及研发投资是业务成长的策略。此外，协调国际监管标准可以简化核准和市场准入。整体而言，市场呈现出动态的特点，其特点是科学的快速进步和监管环境的变化。对研发的策略性投资以及对扩大治疗适应症的关注可以带来巨大的回报。如果持续存在的挑战得到妥善解决，就有充分的机会发展出具有更高功效和安全性的治疗方法。

主要市场统计
基准年[2023] 27.3亿美元
预测年份 [2024] 34.3亿美元
预测年份 [2030] 135.6亿美元
复合年增长率（%） 25.72%

市场动态：揭示快速发展的人工 T 细胞市场的关键市场洞察

供需的动态交互作用正在改变工程 T 细胞市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 癌症盛行率上升
    • 对创新生物製药治疗的需求不断增加
    • CAR-T细胞工程的最新进展
  • 市场限制因素
    • 人工 T 细胞疗法相关的高成本
  • 市场机会
    • 研发经费推动免疫肿瘤学领域蓬勃发展
    • 基因治疗市场的扩大
  • 市场挑战
    • 人工 T 细胞的安全问题与可能的副作用

波特五力：驾驭人工 T 细胞市场的策略工具

波特的五力框架是了解人工 T 细胞市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解人工 T 细胞市场的外部影响

外部宏观环境因素在塑造人工 T 细胞市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解人工T细胞市场的竞争状况

人工 T 细胞市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵人工 T 细胞市场供应商的绩效评估

FPNV定位矩阵是评估工程T细胞市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製人工 T 细胞市场的成功之路

对于想要加强在全球市场的影响力的公司来说，对人工 T 细胞市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 癌症发生率上升
      • 创新生物製药疗法的需求不断增加
      • CAR-T细胞工程的最新进展
    • 抑制因素
      • 工程 T 细胞疗法相关的高成本
    • 机会
      • 研发经费投入推动免疫肿瘤学领域蓬勃发展
      • 基因治疗市场的扩大
    • 任务
      • 人工 T 细胞的安全问题与可能的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 人工 T 细胞市场：依类型

  • 嵌合体抗原受体
  • T细胞受体
  • 肿瘤浸润淋巴细胞

第 7 章 人工 T 细胞市场：依应用分类

  • 乳癌
  • 大肠直肠癌
  • 白血病
  • 肺癌
  • 恶性黑色素瘤

第 8 章 人工 T 细胞市场：依最终用户分类

  • 癌症研究中心
  • 诊所
  • 医院

第九章美洲人工T细胞市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太人工T细胞市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲人工T细胞市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Amgen Inc.
  • Autolus
  • Bellicum Pharmaceuticals, Inc.
  • Bristol Myers Squibb
  • Cabaletta Bio, Inc.
  • ElevateBio, LLC
  • Elli Lilly and Company
  • Gilead
  • Kuur Therapeutics by Athenex
  • Novartis AG
  • Oxford BioMedica
  • Pfizer Inc.
  • Precision Biosciences
  • Tmunity Therapeutics Inc.
  • TScan Therapeutics, Inc.
Product Code: MRR-4348D129FAA9

The Engineered T Cells Market was valued at USD 2.73 billion in 2023, expected to reach USD 3.43 billion in 2024, and is projected to grow at a CAGR of 25.72%, to USD 13.56 billion by 2030.

Engineered T cells, primarily used in immunotherapy, involve modifying patients' T cells to better recognize and attack cancer cells. This scope includes Chimeric Antigen Receptor (CAR) T-cell therapy and T-cell Receptor (TCR) therapy. The necessity of engineered T cells arises from their potential to provide targeted cancer treatments with reduced side effects compared to traditional therapies. Applications extend to various hematologic cancers and some solid tumors. End-use scopes span hospitals, research institutes, and biotechnology companies. Market growth is propelled by advancements in gene-editing technologies, increasing incidences of cancer worldwide, and substantial private and governmental investments. Key opportunities lie in expanding applications in solid tumors, improving safety profiles, and developing off-the-shelf T cell products to enhance accessibility. However, challenges include high treatment costs, complex manufacturing processes, and regulatory hurdles. Market limitations such as severe side effects, potential relapse cases, and ethical concerns regarding genetic modifications also present hurdles. To combat these challenges, innovations in CRISPR-Cas9 for precise gene editing, developing novel biomarkers for better patient selection, and automated manufacturing processes are critical. Research is particularly promising in enhancing tumor microenvironment understanding and tackling cancer cell resistance mechanisms. Pharmaceutical collaborations, strategic partnerships, and investments in R&D are strategies for business growth. Additionally, harmonizing international regulatory standards can streamline approvals and market access. Overall, the market displays a dynamic nature, characterized by rapid scientific advancements and shifting regulatory landscapes. Strategic investments in R&D, coupled with a focus on expanding therapeutic indications, could yield significant dividends. Opportunities are ripe for exploitation in developing therapies with improved efficacy and safety profiles, provided that ongoing challenges are adeptly managed.

KEY MARKET STATISTICS
Base Year [2023] USD 2.73 billion
Estimated Year [2024] USD 3.43 billion
Forecast Year [2030] USD 13.56 billion
CAGR (%) 25.72%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Engineered T Cells Market

The Engineered T Cells Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in prevalence of cancer diseases
    • Increasing demand for innovative biopharmaceutical therapies
    • Recent advances in CAR-T cell engineering
  • Market Restraints
    • High cost associated to engineered T cells treatment
  • Market Opportunities
    • Immuno-oncology sector booming with R&D funding
    • Expanding gene therapy marketspace
  • Market Challenges
    • Safety issues and possible side-effects with engineered T cells

Porter's Five Forces: A Strategic Tool for Navigating the Engineered T Cells Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Engineered T Cells Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Engineered T Cells Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Engineered T Cells Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Engineered T Cells Market

A detailed market share analysis in the Engineered T Cells Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Engineered T Cells Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Engineered T Cells Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Engineered T Cells Market

A strategic analysis of the Engineered T Cells Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Engineered T Cells Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Autolus, Bellicum Pharmaceuticals, Inc., Bristol Myers Squibb, Cabaletta Bio, Inc., ElevateBio, LLC, Elli Lilly and Company, Gilead, Kuur Therapeutics by Athenex, Novartis AG, Oxford BioMedica, Pfizer Inc., Precision Biosciences, Tmunity Therapeutics Inc., and TScan Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Engineered T Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Chimeric Antigen Receptor, T Cell Receptor, and Tumor-Infiltrating Lymphocytes.
  • Based on Application, market is studied across Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, and Melanoma.
  • Based on End-User, market is studied across Cancer Research Centers, Clinics, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in prevalence of cancer diseases
      • 5.1.1.2. Increasing demand for innovative biopharmaceutical therapies
      • 5.1.1.3. Recent advances in CAR-T cell engineering
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated to engineered T cells treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Immuno-oncology sector booming with R&D funding
      • 5.1.3.2. Expanding gene therapy marketspace
    • 5.1.4. Challenges
      • 5.1.4.1. Safety issues and possible side-effects with engineered T cells
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Engineered T Cells Market, by Type

  • 6.1. Introduction
  • 6.2. Chimeric Antigen Receptor
  • 6.3. T Cell Receptor
  • 6.4. Tumor-Infiltrating Lymphocytes

7. Engineered T Cells Market, by Application

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Colorectal Cancer
  • 7.4. Leukemia
  • 7.5. Lung Cancer
  • 7.6. Melanoma

8. Engineered T Cells Market, by End-User

  • 8.1. Introduction
  • 8.2. Cancer Research Centers
  • 8.3. Clinics
  • 8.4. Hospitals

9. Americas Engineered T Cells Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Engineered T Cells Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Engineered T Cells Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. Autolus
  • 3. Bellicum Pharmaceuticals, Inc.
  • 4. Bristol Myers Squibb
  • 5. Cabaletta Bio, Inc.
  • 6. ElevateBio, LLC
  • 7. Elli Lilly and Company
  • 8. Gilead
  • 9. Kuur Therapeutics by Athenex
  • 10. Novartis AG
  • 11. Oxford BioMedica
  • 12. Pfizer Inc.
  • 13. Precision Biosciences
  • 14. Tmunity Therapeutics Inc.
  • 15. TScan Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. ENGINEERED T CELLS MARKET RESEARCH PROCESS
  • FIGURE 2. ENGINEERED T CELLS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ENGINEERED T CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ENGINEERED T CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ENGINEERED T CELLS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ENGINEERED T CELLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ENGINEERED T CELLS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ENGINEERED T CELLS MARKET DYNAMICS
  • TABLE 7. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY T CELL RECEPTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. ENGINEERED T CELLS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. ENGINEERED T CELLS MARKET, FPNV POSITIONING MATRIX, 2023